Graves' disease following administration of second dose of SARS-CoV-2 vaccine

BMJ Case Rep. 2021 Dec 30;14(12):e246432. doi: 10.1136/bcr-2021-246432.


The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves' disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves' disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.

Keywords: COVID-19; thyroid disease; thyrotoxicosis; unwanted effects/adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Graves Disease* / drug therapy
  • Humans
  • SARS-CoV-2


  • COVID-19 Vaccines
  • BNT162 Vaccine